Upgrade to SI Premium - Free Trial

UBS Downgrades Merck (MRK) to Neutral

August 20, 2026 2:49 AM
UBS analyst Matthew Weston downgraded Merck (NYSE: MRK) from Buy to Neutral with a price target of $150.00.The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Downgrades